Patents by Inventor Michael C. BORYS

Michael C. BORYS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12624336
    Abstract: In certain embodiments, this disclosure provides novel methods of increasing the viable cell density of an N?1 large-scale bioreactor cell culture, comprising culturing a host cell expressing a recombinant poly peptide of interest in a non-perfusion-based culture system, and wherein the viable cell density is increased to at least 5×106 cells/mL. In certain embodiments, the disclosure provides novel methods for large-scale production of a recombinant polypeptide of interest, comprising: (1) culturing a host cell expressing a recombinant polypeptide of interest in an N?1 stage in a non-perfusion-based culture system, wherein the viable cell density is increased to at least 5×106 cells/mL; and (2) culturing N fed-batch production cells in an enriched media with high-seed density at least 1.5×106 cells/mL, wherein the N fed-batch production cells are inoculated from the N-1 stage in a non-perfusion-based culture system.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: May 12, 2026
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jianlin Xu, Andrew Yongky, Jun Tian, Michael C. Borys, Zhengjian Li
  • Publication number: 20250171732
    Abstract: In certain embodiments, this disclosure provides novel methods of increasing the viable cell density of an N-1 large-scale bioreactor cell culture, comprising culturing a host cell expressing a recombinant poly peptide of interest in a non-perfusion-based culture system, and wherein the viable cell density is increased to at least 5×106 cells/mL. In certain embodiments, the disclosure provides novel methods for large-scale production of a recombinant polypeptide of interest, comprising: (1) culturing a host cell expressing a recombinant polypeptide of interest in an N-1 stage in a non-perfusion-based culture system, wherein the viable cell density is increased to at least 5×106 cells/mL: and (2) culturing N fed-batch production cells in an enriched media with high-seed density at least 1.5×106 cells/mL, wherein the N fed-batch production cells are inoculated from the N-1 stage in a non-perfusion-based culture system.
    Type: Application
    Filed: January 17, 2025
    Publication date: May 29, 2025
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jianlin XU, Andrew YONGKY, Jun TIAN, Michael C. BORYS, Zhengjian LU
  • Publication number: 20210253996
    Abstract: In certain embodiments, this disclosure provides novel methods of increasing the viable cell density of an N-1 large-scale bioreactor cell culture, comprising culturing a host cell expressing a recombinant polypeptide of interest in a non-perfusion-based culture system, and wherein the viable cell density is increased to at least 5×106 cells/mL. In certain embodiments, the disclosure provides novel methods for large-scale production of a recombinant polypeptide of interest, comprising: (1) culturing a host cell expressing a recombinant polypeptide of interest in an N-1 stage in a non-perfusion-based culture system, wherein the viable cell density is increased to at least 5×106 cells/mL; and (2) culturing N fed-batch production cells in an enriched media with high-seed density at least 1.5×106 cells/mL, wherein the N fed-batch production cells are inoculated from the N-1 stage in a non-perfusion-based culture system.
    Type: Application
    Filed: July 2, 2019
    Publication date: August 19, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jianlin XU, Andrew YONGKY, Jun TIAN, Michael C. BORYS, Zhengjian LU